Stiff Person Syndrome (SPS) is a rare neurological condition that affects approximately one in a million people, according to the National Organization for Rare Disorders (NORD). It is a progressive disorder of the central nervous system that can lead to permanent disability or death if left untreated. The symptoms of SPS typically develop slowly over months or years, starting with muscle stiffness and discomfort that can come and go but eventually become fixed. Some individuals with SPS develop a “statue-like” appearance due to the rigidity of their muscles.
Painful muscle spasms are also common in SPS and can last from a few minutes to several hours. These spasms can be triggered by loud noises, minor physical contact, cold environments, stress, or emotionally intense situations. Chest and respiratory muscle spasms can be serious and may require emergency treatment or ventilation, while spasms in the legs often lead to falls.
The exact cause of SPS is still unknown, and the condition is often underdiagnosed. It is more prevalent in females than males and is frequently associated with other autoimmune diseases such as type-I diabetes, thyroiditis, vitiligo, and pernicious anemia. While there is no cure for SPS, various treatments can help alleviate the symptoms. Anti-seizure drugs, painkillers, and anti-anxiety medication are commonly used to manage the condition. Drugs that alleviate muscle spasms, such as baclofen or gabapentin, can also be effective.
Celine Dion, the renowned singer, announced in 2022 that she had been diagnosed with Stiff Person Syndrome. Due to difficulties associated with the condition, she decided to cancel the remainder of her Courage World Tour. Dion expressed her apologies to her fans and assured them that she would not give up, eagerly anticipating the opportunity to perform again in the future. As a singer, Dion may be particularly sensitive to triggers such as bright lights and loud noises, which could induce muscle spasms associated with SPS.
 is a rare neurological condition that affects approximately one in a million people, according to the National Organization for Rare Disorders (NORD).){kind=link}